Photo by omarprestwich from unsplash
zumab, Secukinumab, and Brodalumab) are being evaluated for treatments of psoriasis, psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis. The current study by Gomes and coworkers adds interesting insights into the… Click to show full abstract
zumab, Secukinumab, and Brodalumab) are being evaluated for treatments of psoriasis, psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis. The current study by Gomes and coworkers adds interesting insights into the cellular and molecular mechanisms underlying IL-17-driven NAFLD progression, giving rise to the hope that the findings can be translated into novel therapeutics for NAFLD in the future.
Keywords:
t39 step;
closer treating;
lxr inhibiting;
inhibiting t39;
preserving lxr;
step closer
Journal Title: Hepatology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Hepatology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!